Investors
Overview

Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Press Releases
Read more
Recent/Upcoming Events
Nov 15, 2024 at 1:00 PM PST
AASLD – The Liver Meeting

Presentation Title: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Plasma Lipidomic Profiles in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Speaker: Sarah Browne, M.D., Vice President, Clinical Development, Altimmune

 

View all

Corporate Governance

Corporate Presentation
 

Investor Contact

Email: ir@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe